GlassScriptPhysician profile
Tricia Andrews
NPI 1427031509
$5,953.18
in general payments reported to CMS, 2019-2025
24 companies · $1,132 in 2025
The $1,132 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $977 · 2020: $538 · 2021: $581 · 2022: $895 · 2023: $812 · 2024: $1,019 · 2025: $1,132.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,864 · Education: $99.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,863.54 |
| Education | $99.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $1,850.37 | 2019-2025 | |
| Abbvie INC. | $814.07 | 2019-2025 | Rinvoq, Skyrizi |
| Regeneron Healthcare Solutions, INC. | $707.22 | 2019-2025 | Dupixent |
| Amgen INC. | $343.42 | 2020-2025 | Otezla, Otezla |
| Novartis Pharmaceuticals Corporation | $339.24 | 2019-2025 | |
| Janssen Biotech, INC. | $328.84 | 2019-2025 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $236.86 | 2022-2025 | Sotyktu |
| Incyte Corporation | $235.23 | 2021-2025 | Opzelura |
| Lilly USA, LLC | $203.42 | 2019-2025 | Ebglyss, Taltz, Olumiant |
| Sun Pharmaceutical Industries INC. | $185.04 | 2019-2025 | Winlevi, Absorica Ld |
| Almirall LLC | $123.31 | 2019-2025 | Klisyri |
| Pfizer INC. | $93.31 | 2019-2024 | |
| Sebela Pharmaceuticals INC. | $92.72 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $76.36 | 2019-2025 | Cabtreo |
| Galderma Laboratories, L.P. | $75.67 | 2019-2025 | Aklief |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Arcutis Biotherapeutics, INC. | $69.94 | 2024-2025 | Zoryve |
| Celgene Corporation | $45.04 | 2019 | |
| Mayne Pharma Commercial LLC | $31.29 | 2023-2025 | |
| Vyne Pharmaceuticals INC. | $22.97 | 2020 | |
| Sandoz INC. | $18.52 | 2019 | |
| Sanofi-Aventis U.S. LLC | $17.33 | 2021 | |
| Helsinn Therapeutics (U.S.), INC. | $16.40 | 2022 | |
| Verrica Pharmaceuticals INC. | $13.61 | 2023 | Ycanth |
| Glenmark Therapeutics INC. | $13.00 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tricia Andrews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.